Cite
Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial.
MLA
Bauer, Axel, et al. “Telemedical Cardiac Risk Assessment by Implantable Cardiac Monitors in Patients after Myocardial Infarction with Autonomic Dysfunction (SMART-MI-DZHK9): A Prospective Investigator-Initiated, Randomised, Multicentre, Open-Label, Diagnostic Trial.” The Lancet. Digital Health, vol. 4, no. 2, Feb. 2022, pp. e105–16. EBSCOhost, https://doi.org/10.1016/S2589-7500(21)00253-3.
APA
Bauer, A., Sappler, N., von Stülpnagel, L., Klemm, M., Schreinlechner, M., Wenner, F., Schier, J., Al Tawil, A., Dolejsi, T., Krasniqi, A., Eiffener, E., Bongarth, C., Stühlinger, M., Huemer, M., Gori, T., Wakili, R., Sahin, R., Schwinger, R., Lutz, M., … Massberg, S. (2022). Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial. The Lancet. Digital Health, 4(2), e105–e116. https://doi.org/10.1016/S2589-7500(21)00253-3
Chicago
Bauer, Axel, Nikolay Sappler, Lukas von Stülpnagel, Mathias Klemm, Michael Schreinlechner, Felix Wenner, Johannes Schier, et al. 2022. “Telemedical Cardiac Risk Assessment by Implantable Cardiac Monitors in Patients after Myocardial Infarction with Autonomic Dysfunction (SMART-MI-DZHK9): A Prospective Investigator-Initiated, Randomised, Multicentre, Open-Label, Diagnostic Trial.” The Lancet. Digital Health 4 (2): e105–16. doi:10.1016/S2589-7500(21)00253-3.